title: Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.
authors.forename: R J
authors.initials: RJ
authors.lastname: Pepper
authors.forename: M A
authors.initials: MA
authors.lastname: Fabre
authors.forename: C
authors.initials: C
authors.lastname: Pavesio
authors.forename: G
authors.initials: G
authors.lastname: Gaskin
authors.forename: R B
authors.initials: RB
authors.lastname: Jones
authors.forename: D
authors.initials: D
authors.lastname: Jayne
authors.forename: C D
authors.initials: CD
authors.lastname: Pusey
authors.forename: A D
authors.initials: AD
authors.lastname: Salama
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015267:Churg-Strauss Syndrome / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015848:Interleukin-5 / Q000096:biosynthesis*; D008297:Male; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D015848:Interleukin-5; D000069283:Rituximab